• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    3M Delivers Strong Fourth-Quarter Results; Improves Operational Performance and Exceeds Earnings and Cash Flow Expectations

    1/23/24 6:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care
    Get the next $MMM alert in real time by email
    • Results reflect strong operational execution, progress on restructuring, and spending discipline
    • Well-positioned to continue improving performance, including continued expansion of adjusted operating margins3 in 2024
    • Health Care spin remains on track for first half of 2024

    ST. PAUL, Minn., Jan. 23, 2024 /PRNewswire/ -- 3M (NYSE:MMM) today reported fourth-quarter and full-year 2023 results and provided its 2024 financial outlook.

    "The fourth quarter capped a strong year for 3M," said 3M chairman and CEO Mike Roman. "Throughout 2023, we executed our priorities and delivered on our commitments – including expanding underlying operating margins and cash flow. We initiated actions to restructure our organization and simplify our supply chain, while progressing our Health Care spin and addressing legal matters."

    "Our team remains focused on further improving our operational performance, optimizing our portfolio, and reducing risk," Roman continued. "We will continue to invest in high-growth markets where 3M's unique capabilities can make a difference, including automotive electrification, climate technology, and industrial automation. I am confident we will deliver a successful 2024."

    Fourth-Quarter Highlights:











    Q4 2023



    Q4 2022









    GAAP earnings per share



    $          1.70



    $          0.98









         Special items:

















              Net costs for significant litigation



    0.36



    0.07









              Other special items, net



    0.36



    1.13









    Adjusted earnings per share (EPS)



    $          2.42



    $          2.18



























    Memo:

















         GAAP operating income margin



    15.5 %



    7.8 %









         Adjusted operating income margin1



    20.9 %



    19.1 %









    1Above adjusted operating income margin for Q4 2023 includes a 1.4 percentage point headwind

    from restructuring related net charges.



    • GAAP earnings per share of $1.70 and operating margin of 15.5%.
    • Adjusted EPS of $2.42 includes pre-tax restructuring related net charges of $109 million, or negative $0.17 per share.
      • Adjusted EPS up 11 percent year-on-year.
    • Adjusted operating income margin of 20.9% includes a 1.4 percentage point headwind from restructuring related net charges.
      • Adjusted operating income margin expanded 1.8 percentage points year-on-year.










    GAAP



    Adjusted (Non-

    GAAP)









    Net sales (Millions)



    $8,013



    $7,693









    Sales change

















    Total sales



    (0.8) %



    (0.3) %









         Components of sales change:

















              Organic sales2



    (1.9) %



    (1.4) %









              Acquisitions/divestitures



    0.2 %



    0.2 %









              Translation



    0.9 %



    0.9 %









    Adjusted sales excludes manufactured PFAS products.









    2Above adjusted organic sales decline includes a 60 basis point headwind from the decline in

    disposable respirator demand.



    • Sales of $8.0 billion, down 0.8 percent year-on-year, with organic sales decline of 1.9 percent year-on-year.
    • Adjusted sales of $7.7 billion, down 0.3 percent year-on-year with adjusted organic sales decline of 1.4 percent year-on-year.
    • Operating cash flow of $2.0 billion, up 3 percent year-on-year; adjusted free cash flow of $2.0 billion, up 18 percent year-on-year.
    • 3M returned $828 million to shareholders via dividends.

    The above includes reference to certain non-GAAP measures. See the "Supplemental Financial Information Non-GAAP Measures" section for applicable information.

    Full-Year Highlights:











    Full Year

    2023



    Full Year

    2022









    GAAP earnings (loss) per share



    $      (12.63)



    $        10.18









         Special items:

















              Impact of Combat Arms Earplug (CAE) settlement



    5.94



    —









              Impact of public water systems (PWS) settlement



    14.45



    —









              Other net costs for significant litigation



    0.61



    3.20









              Other special items, net



    0.87



    (3.50)









    Adjusted earnings per share (EPS)



    $          9.24



    $          9.88



























    Memo:

















         GAAP operating income (loss) margin



    (27.9) %



    19.1 %









         Adjusted operating income margin1



    20.3 %



    21.1 %









    1Above adjusted operating income margin for full year 2023 includes a 1.4 percentage point

    headwind from restructuring related net charges.



    • GAAP loss per share of $12.63 and operating margin of minus 27.9% includes the previously announced settlements for CAE and PWS in the United States regarding PFAS, resulting in a pre-tax charges of $4.3 billion and $10.5 billion, respectively, negatively impacting EPS by a total of $20.39.
    • Adjusted EPS of $9.24 includes pre-tax restructuring related net charges of $441 million, or negative $0.65 per share.
    • Adjusted operating income margin of 20.3% includes a 1.4 percentage point headwind from restructuring related net charges.










    GAAP



    Adjusted (Non-

    GAAP)









    Net sales (Millions)



    $32,681



    $31,392









    Sales change

















    Total sales



    (4.5) %



    (4.5) %









         Components of sales change:

















              Organic sales2



    (3.2) %



    (3.2) %









              Acquisitions/divestitures



    (0.7) %



    (0.8) %









              Translation



    (0.6) %



    (0.5) %









    Adjusted sales excludes manufactured PFAS products.









    2Above adjusted organic sales decline includes a 1.9 percentage point headwind from the decline in

    disposable respirator demand, along with the 2022 exit of Russia.



    • Sales of $32.7 billion, down 4.5 percent year-on-year, with organic sales decline of 3.2 percent year-on-year.
    • Adjusted sales of $31.4 billion, down 4.5 percent year-on-year with adjusted organic sales decline of 3.2 percent year-on-year.
    • Operating cash flow of $6.7 billion, up 19 percent year-on-year; adjusted free cash flow of $6.3 billion, up 30 percent year-on-year. Year-on-year improvement driven by ongoing focus on working capital management, especially inventory.
    • 3M returned $3.3 billion to shareholders via dividends.

    The above includes reference to certain non-GAAP measures. See the "Supplemental Financial Information Non-GAAP Measures" section for applicable information.

    Full-Year 2024 Outlook

    3M provided the following full-year 2024 expectations. This 2024 outlook continues to reflect the Health Care business as part of the company for the full year, but does not reflect the potential impact of funding amounts due under the PWS and CAE legal settlements absent receipt of cash payments in the Health Care business spin.

    • Adjusted total sales growth3 in the range of 0.25 to 2.25 percent, reflecting adjusted organic sales3 growth of flat to up 2 percent.
    • Adjusted EPS3 in the range of $9.35 to $9.75.
    • Adjusted operating cash flow3 of $6.5 to $7.1 billion, contributing to 95 to 105 percent adjusted free cash flow conversion3.

    The above does not reflect, for reasons described at 3, the potential impact of funding amounts under the PWS and CAE settlements absent cash received in the Health Care spin. However, for illustrative purposes only, adjusted EPS3 could be impacted up to an estimated ($0.20) from complete debt financing of these settlements based on current market and company expectations.

    3As further discussed at 7 within the "Supplemental Financial Information Non-GAAP Measures" section, 3M cannot, without unreasonable effort, forecast certain items required to develop meaningful comparable GAAP financial measures and, therefore, does not provide them on a forward-looking basis reflecting these items.

    Conference Call

    3M will conduct an investor teleconference at 9 a.m. EST (8 a.m. CST) today. Investors can access this conference via the following:

    • Live webcast at https://investors.3M.com 
    • Live telephone:

      Call 800-762-2596 within the U.S. or +1 212-231-2916 outside the U.S. Please join the call at least 10 minutes before the start time.
    • Webcast replay at https://investors.3m.com/financials/quarterly-earnings
    • Telephone replay:

      Call 800-633-8284 within the U.S. or +1 402-977-9140 outside the U.S. (for both U.S. and outside the U.S., the access code is 22028938). The telephone replay will be available until 11:30 a.m. EST (10:30 a.m. CST) on January 30, 2024.

    Consolidated Financial Statements and Supplemental Financial Information Non-GAAP Measures

    View the Financial Statement Information on 3M's website: https://investors.3m.com/financials/quarterly-earnings

    Forward-Looking Statements

    This news release contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "plan," "expect," "aim," "believe," "project," "target," "anticipate," "intend," "estimate," "will," "should," "could," "would," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, international trade, geopolitical, capital markets and other external conditions and other factors beyond the Company's control, including inflation, recession, military conflicts, natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) foreign currency exchange rates and fluctuations in those rates; (3) risks related to certain fluorochemicals, including liabilities related to claims, lawsuits, and government regulatory proceedings concerning various PFAS-related products and chemistries, as well as risks related to the Company's plans to exit PFAS manufacturing and discontinue use of PFAS across its product portfolio; (4) risks related to the proposed class-action settlement ("PWS Settlement") to resolve claims by public water systems in the United States regarding PFAS, including whether court approval of the PWS Settlement will be obtained, whether the number of plaintiffs that opt out of the PWS Settlement will exceed current expectations or will exceed the level that would permit 3M to terminate the PWS Settlement (and whether 3M will elect to terminate the PWS Settlement if this occurs), whether the PWS Settlement is appealed, the timing and amount of payments made under the PWS Settlement, and the impact of the PWS Settlement on other PFAS-related matters; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2022 and any subsequent quarterly reports on Form 10-Q (the "Reports"); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product and service offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy due to shortages, increased demand and wages, supply chain interruptions, or natural or other disasters; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other strategic events resulting from portfolio management actions and other evolving business strategies; (11) operational execution, including the extent to which the Company can realize the benefits of planned productivity improvements, as well as the impact of organizational restructuring activities; (12) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company's Health Care business, including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company's ability to retain talent; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the transaction; and (16) matters relating to Combat Arms Earplugs ("CAE"), including those relating to, the August 2023 settlement that is intended to resolve, to the fullest extent possible, all litigation and alleged claims involving the CAE sold or manufactured by the Company's subsidiary Aearo Technologies and certain of its affiliates ("Aearo Entities") and/or 3M ("CAE Settlement"), including, but not limited to, whether the anticipated participation by plaintiffs in the CAE Settlement will be achieved, whether the number of plaintiffs that participate in the CAE Settlement will meet current expectations or will fall below the level that would permit 3M to terminate the CAE Settlement (and whether 3M will elect to terminate the CAE Settlement if this occurs), whether there will be a significant number of future claims by plaintiffs that decline to participate in the CAE Settlement, whether the CAE Settlement is appealed or challenged, matters related to the potential issuance of the equity securities that are contemplated to be part of the CAE Settlement, the filing of additional, or the outcome of any other pending or future, litigation relating to the products that are the subject of the CAE Settlement, or changes in related laws or regulations. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

    About 3M

    3M (NYSE:MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news.

    Please note that the company announces material financial, business and operational information using the 3M investor relations website, SEC filings, press releases, public conference calls and webcasts. The company also uses the 3M News Center and social media to communicate with our customers and the public about the company, products and services and other matters. It is possible that the information 3M posts on the News Center and social media could be deemed to be material information. Therefore, the company encourages investors, the media and others interested in 3M to review the information posted on 3M's news center and the social media channels such as @3M or @3MNews.

    Contacts

    3M

    Investor Contacts:

    Bruce Jermeland, 651-733-1807

    or

    Diane Farrow, 612-202-2449

    or

    Eric Herron, 651-233-0043

    Media Contact:

    Tim Post, [email protected] 

    3M (PRNewsfoto/3M)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-delivers-strong-fourth-quarter-results-improves-operational-performance-and-exceeds-earnings-and-cash-flow-expectations-302041325.html

    SOURCE 3M Company

    Get the next $MMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MMM

    DatePrice TargetRatingAnalyst
    1/16/2026$182.00Overweight → Neutral
    Analyst
    12/8/2025$178.00Buy → Hold
    Deutsche Bank
    10/22/2025$160.00Underweight → Equal-Weight
    Morgan Stanley
    1/22/2025$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    11/13/2024$184.00Neutral → Buy
    UBS
    10/22/2024Hold → Buy
    Melius
    9/6/2024$125.00Underweight
    Morgan Stanley
    7/30/2024$145.00Hold → Buy
    Argus
    More analyst ratings

    $MMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: EVP, Chief Legal Off & Secret Rhodes Kevin H covered exercise/tax liability with 5,837 shares, decreasing direct ownership by 15% to 32,633 units (SEC Form 4)

    4/A - 3M CO (0000066740) (Issuer)

    2/18/26 4:14:11 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Amendment: EVP & Chief Info Digital Off Murphy Mark W. covered exercise/tax liability with 4,793 shares, decreasing direct ownership by 27% to 13,025 units (SEC Form 4)

    4/A - 3M CO (0000066740) (Issuer)

    2/18/26 4:12:20 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Amendment: EVP & Chief HR Officer Dickson Zoe L covered exercise/tax liability with 475 shares, decreasing direct ownership by 3% to 17,666 units (SEC Form 4)

    4/A - 3M CO (0000066740) (Issuer)

    2/18/26 4:10:40 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    3M downgraded by Analyst with a new price target

    Analyst downgraded 3M from Overweight to Neutral and set a new price target of $182.00

    1/16/26 8:27:24 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded 3M from Buy to Hold and set a new price target of $178.00

    12/8/25 8:20:58 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded 3M from Underweight to Equal-Weight and set a new price target of $160.00

    10/22/25 6:59:04 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 22, 2021 - Coronavirus (COVID-19) Update: January 22, 2021

    For Immediate Release: January 22, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found th

    1/22/21 3:54:10 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    SEC Filings

    View All

    $MMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    3M Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - 3M CO (0000066740) (Filer)

    2/5/26 8:32:39 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form S-3ASR filed by 3M Company

    S-3ASR - 3M CO (0000066740) (Filer)

    2/3/26 4:50:35 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form IRANNOTICE filed by 3M Company

    IRANNOTICE - 3M CO (0000066740) (Filer)

    2/3/26 4:15:06 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M appoints Meagan Linn as Senior Vice President, Government Affairs

    ST. PAUL, Minn., Feb. 16, 2026 /PRNewswire/ -- 3M today announced the appointment of Meagan Linn as Senior Vice President, Government Affairs. In this role, Linn will oversee the company's engagement with the executive branch, policymakers, regulatory agencies, and industry associations, globally to advance public policy dialogue. She will also be responsible for developing business growth through government contracts. Linn brings 20 years of experience in public policy, with 12 years at Northrop Grumman Corporation, most recently as government policy lead and Chief of Staff, an

    2/16/26 10:00:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Announces New Board Appointment

    Neil Mitchill elected to the Board of Directors ST. PAUL, Minn., Feb. 5, 2026 /PRNewswire/ -- 3M (NYSE:MMM) announced today the election of Neil G. Mitchill, Jr. to 3M's Board of Directors, effective Feb. 6, 2026. Mr. Mitchill also has been appointed as a member of the Audit Committee and the Nominating and Governance Committee of the Board. Mr. Mitchill is the Executive Vice President and Chief Financial Officer, RTX Corporation. Holding this position since 2021, his responsibilities span financial reporting and controls, planning and analysis, investor relations, internal audit, tax and treasury. Prior to his current role, Mr. Mitchill served as Corporate Vice President of Financial Planni

    2/5/26 8:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Board Declares Quarterly Dividend

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- The 3M Company Board of Directors (NYSE:MMM) today declared a dividend on the company's common stock of $0.78 per share for the first quarter of 2026. The dividend is payable March 12, 2026, to shareholders of record at the close of business on Feb. 13, 2026. 3M has paid dividends to its shareholders without interruption for more than 100 years. About 3M 3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global foo

    2/3/26 4:10:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Leadership Updates

    Live Leadership Updates

    View All

    3M appoints Meagan Linn as Senior Vice President, Government Affairs

    ST. PAUL, Minn., Feb. 16, 2026 /PRNewswire/ -- 3M today announced the appointment of Meagan Linn as Senior Vice President, Government Affairs. In this role, Linn will oversee the company's engagement with the executive branch, policymakers, regulatory agencies, and industry associations, globally to advance public policy dialogue. She will also be responsible for developing business growth through government contracts. Linn brings 20 years of experience in public policy, with 12 years at Northrop Grumman Corporation, most recently as government policy lead and Chief of Staff, an

    2/16/26 10:00:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Lanvin Group Announces Appointment of New Chief Financial Officer

    SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- Lanvin Group (NYSE:LANV), a global luxury fashion group, today announced the appointment of Mr. Jiyang Han as Chief Financial Officer (CFO) of the Company, effective November 1, 2025. In this role, Mr. Han will oversee the Group's financial affairs, including financial planning and analysis, accounting and controllership, financial management, treasury, investment and financing projects, and investor relations.  Mr. Han brings nearly two decades of experience in corporate finance, investment banking, and global business management. He has served as Co-CIO and Assistant President of Yuyuan (SHSE: 600655) since June 2025. Prior to that, he was the M&A a

    10/24/25 6:00:00 AM ET
    $LANV
    $MMM
    Apparel
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    3M Annual Meeting Results

    ST. PAUL, Minn., May 13, 2025 /PRNewswire/ -- At today's Annual Meeting of Shareholders, 3M (NYSE:MMM) shareholders overwhelmingly supported each of the proposals recommended for approval by the company. Preliminary Shareholder Voting Results 3M shareholders today voted on the following business items: 1) Shareholders supported 11 directors for one-year terms to expire at the company's 2026 Annual Meeting: David P. Bozeman, President, Chief Executive Officer and Director, C.H. Robinson Worldwide, Inc.Thomas "Tony" K. Brown, retired Group Vice President, Global Purchasing, Ford

    5/13/25 4:30:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/13/24 4:56:03 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/9/23 10:54:46 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/9/22 3:15:56 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Financials

    Live finance-specific insights

    View All

    3M Board Declares Quarterly Dividend

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- The 3M Company Board of Directors (NYSE:MMM) today declared a dividend on the company's common stock of $0.78 per share for the first quarter of 2026. The dividend is payable March 12, 2026, to shareholders of record at the close of business on Feb. 13, 2026. 3M has paid dividends to its shareholders without interruption for more than 100 years. About 3M 3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global foo

    2/3/26 4:10:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Reports Fourth-Quarter and Full-Year 2025 Results; Initiates Full-Year 2026 Financial Guidance

    Q4 GAAP sales of $6.1 billion, up 2.1%; operating margin of 13.0%, down 510 bps; EPS of $1.07, down 20%, all YoYAdjusted sales of $6.0 billion with organic growth of 2.2% YoYAdjusted operating margin of 21.1%, up 140 bps YoYAdjusted EPS of $1.83, up 9% YoYQ4 operating cash flow of $1.6 billion with adjusted free cash flow of $1.3 billionFull-year GAAP sales of $24.9 billion, up 1.5%; operating margin of 18.6%, down 100 bps; EPS of $6.00, down 17%, all YoYAdjusted sales of $24.3 billion with organic growth of 2.1% YoYAdjusted operating margin of 23.4%, up 200 bps YoYAdjusted EPS of $8.06, up 10% YoYFull-year operating cash flow of $2.3 billion with adjusted free cash flow of $4.4 billionST. P

    1/20/26 6:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Announces Upcoming Investor Event

    ST. PAUL, Minn., Jan. 6, 2026 /PRNewswire/ -- 3M (NYSE:MMM) today announced the following investor event: Fourth-quarter 2025 earnings conference call on Tuesday, Jan. 20, 2026, at 8 a.m. CT.This event will be webcast live and a replay will be available on 3M's Investor Relations website at http://investors.3M.com. About 3M3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3

    1/6/26 10:15:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care